Guided Thera Financials

GTHP

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Guided Thera (GTHP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Guided Thera passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.46x

For every $1 of reported earnings, Guided Thera generates $0.46 in operating cash flow (-$1.1M OCF vs -$2.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.5x

Guided Thera earns $-5.5 in operating income for every $1 of interest expense (-$2.1M vs $381K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$7K

YoY-92.9%

5Y CAGR-27.9%

10Y CAGR-20.0%

Guided Thera generated $7K in revenue in fiscal year 2024. This represents a decrease of 92.9% from the prior year.

EBITDA

-$2.1M

YoY+39.1%

Guided Thera's EBITDA was -$2.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 39.1% from the prior year.

Free Cash Flow

N/A

Net Income

-$2.4M

YoY+30.7%

Guided Thera reported -$2.4M in net income in fiscal year 2024. This represents an increase of 30.7% from the prior year.

EPS (Diluted)

$-0.05

YoY+28.6%

Guided Thera earned $-0.05 per diluted share (EPS) in fiscal year 2024. This represents an increase of 28.6% from the prior year.

Cash & Debt

$388K

YoY-34.3%

5Y CAGR-15.5%

10Y CAGR+9.1%

Guided Thera held $388K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

65M

YoY+20.4%

Guided Thera had 65M shares outstanding in fiscal year 2024. This represents an increase of 20.4% from the prior year.

Gross Margin

28.6%

YoY-8.2pp

5Y CAGR+123.0pp

10Y CAGR+233.2pp

Guided Thera's gross margin was 28.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 8.2 percentage points from the prior year.

Operating Margin

-30114.3%

YoY-26586.7pp

5Y CAGR-27511.5pp

10Y CAGR-16777.4pp

Guided Thera's operating margin was -30114.3% in fiscal year 2024, reflecting core business profitability. This is down 26586.7 percentage points from the prior year.

Net Margin

-34528.6%

YoY-30968.4pp

5Y CAGR-29192.5pp

10Y CAGR-19324.0pp

Guided Thera's net profit margin was -34528.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 30968.4 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$526K

YoY+130.7%

5Y CAGR+33.9%

10Y CAGR-15.4%

Guided Thera invested $526K in research and development in fiscal year 2024. This represents an increase of 130.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GTHP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$7K-92.9%	$98K+653.8%	$13K-84.0%	$81K-20.6%	$102K+183.3%	$36K
Cost of Revenue	$5K-91.9%	$62K-23.5%	$81K+32.8%	$61K+248.8%	-$41K-158.6%	$70K
Gross Profit	$2K-94.4%	$36K+152.9%	-$68K-440.0%	$20K	N/A	-$34K
R&D Expenses	$526K+130.7%	$228K+196.1%	$77K+11.6%	$69K-51.7%	$143K+17.2%	$122K
SG&A Expenses	$1.3M-56.7%	$3.0M-0.3%	$3.0M+38.4%	$2.2M+137.9%	$913K+31.6%	$694K
Operating Income	-$2.1M+39.0%	-$3.5M-3.7%	-$3.3M-41.1%	-$2.4M-124.5%	-$1.1M-12.3%	-$937K
Interest Expense	$381K+37.1%	$278K-52.2%	$582K-49.4%	$1.1M+8.9%	$1.1M-25.2%	$1.4M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$2.4M+30.7%	-$3.5M+19.6%	-$4.3M-109.7%	-$2.1M-641.9%	-$279K+85.5%	-$1.9M
EPS (Diluted)	$-0.05+28.6%	$-0.07+53.3%	$-0.15+16.7%	$-0.18-350.0%	$-0.04	$-0.58

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$60K-48.7%	$117K	$0-100.0%	$1K	$0-100.0%	$6K-81.3%	$32K	$0
Cost of Revenue	$25K-34.2%	$38K	$0-100.0%	$3K	$0-100.0%	$2K-87.5%	$16K+300.0%	$4K
Gross Profit	$35K-55.7%	$79K	$0+100.0%	-$2K	$0-100.0%	$4K-75.0%	$16K+500.0%	-$4K
R&D Expenses	$136K+2.3%	$133K+79.7%	$74K-46.8%	$139K-37.4%	$222K+311.1%	$54K-37.2%	$86K+24.6%	$69K
SG&A Expenses	$362K-45.0%	$658K+146.4%	$267K-17.3%	$323K-11.3%	$364K+54.2%	$236K-32.8%	$351K-27.0%	$481K
Operating Income	-$485K+36.4%	-$763K-84.3%	-$414K+22.3%	-$533K+18.6%	-$655K-82.5%	-$359K+26.1%	-$486K+22.0%	-$623K
Interest Expense	$129K-17.8%	$157K+6.8%	$147K+9.7%	$134K+78.7%	$75K+17.2%	$64K-11.1%	$72K+1.4%	$71K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$742K+8.5%	-$811K-189829.7%	-$427+100.0%	-$1.1M-48.6%	-$709K-176268.2%	-$402+99.9%	-$386K+43.0%	-$677K
EPS (Diluted)	$-0.010.0%	$-0.010.0%	$-0.01+50.0%	$-0.02-100.0%	$-0.010.0%	$-0.010.0%	$-0.010.0%	$-0.01

GTHP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$1.4M-17.4%	$1.7M-50.4%	$3.4M+65.0%	$2.0M+51.1%	$1.4M+14.4%	$1.2M
Current Assets	$1.2M-14.1%	$1.4M-53.6%	$3.0M+83.5%	$1.6M+82.7%	$896K-13.0%	$1.0M
Cash & Equivalents	$388K-34.3%	$591K-74.4%	$2.3M+259.7%	$643K+253.3%	$182K-79.8%	$899K
Inventory	$633K+0.2%	$632K+15.3%	$548K-4.0%	$571K-5.6%	$605K+1160.4%	$48K
Accounts Receivable	$3K-57.1%	$7K+16.7%	$6K-87.0%	$46K+91.7%	$24K+84.6%	$13K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.3M+14.5%	$5.5M-12.4%	$6.2M-16.5%	$7.5M-38.7%	$12.2M-32.6%	$18.1M
Current Liabilities	$6.2M+28.0%	$4.8M-1.2%	$4.9M-14.5%	$5.7M-36.5%	$9.0M-27.8%	$12.4M
Long-Term Debt	N/A	N/A	$0-100.0%	$22K-4.3%	$23K	$0
Total Equity	-$4.9M-28.5%	-$3.8M-32.0%	-$2.9M+47.1%	-$5.4M+49.8%	-$10.9M+35.9%	-$16.9M
Retained Earnings	-$153.7M-1.7%	-$151.1M-2.6%	-$147.4M-3.5%	-$142.4M-1.7%	-$140.0M-0.3%	-$139.6M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$903K-3.9%	$940K-2.8%	$967K-29.8%	$1.4M+10.2%	$1.3M-16.3%	$1.5M-10.5%	$1.7M-11.1%	$1.9M
Current Assets	$799K-1.5%	$811K0.0%	$811K-32.2%	$1.2M+17.2%	$1.0M-17.7%	$1.2M-11.0%	$1.4M-11.7%	$1.6M
Cash & Equivalents	$87K-53.0%	$185K+60.9%	$115K-70.4%	$388K+41.1%	$275K-38.2%	$445K-24.7%	$591K-19.2%	$731K
Inventory	$583K-2.0%	$595K-6.0%	$633K0.0%	$633K+0.2%	$632K0.0%	$632K0.0%	$632K-2.5%	$648K
Accounts Receivable	$6K-25.0%	$8K+300.0%	$2K-33.3%	$3K+50.0%	$2K-71.4%	$7K0.0%	$7K0.0%	$7K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.5M+2.1%	$6.4M+7.0%	$6.0M-4.3%	$6.3M+5.9%	$5.9M+7.5%	$5.5M+0.6%	$5.5M-0.9%	$5.5M
Current Liabilities	$6.5M+1.5%	$6.4M+8.1%	$5.9M-4.2%	$6.2M+7.4%	$5.7M+7.3%	$5.3M+11.1%	$4.8M-0.5%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$5.6M-3.2%	-$5.5M-8.8%	-$5.0M-2.8%	-$4.9M-4.8%	-$4.7M-16.3%	-$4.0M-5.4%	-$3.8M-4.3%	-$3.6M
Retained Earnings	-$155.8M-0.5%	-$155.0M-0.6%	-$154.2M-0.3%	-$153.7M-0.9%	-$152.3M-0.5%	-$151.6M-0.3%	-$151.1M-0.3%	-$150.6M

GTHP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$1.1M+35.9%	-$1.7M-18.1%	-$1.5M+7.1%	-$1.6M+15.1%	-$1.9M-132.6%	-$806K
Capital Expenditures	N/A	$0-100.0%	$31K+121.4%	$14K+1300.0%	$1K	$0
Free Cash Flow	N/A	-$1.7M-15.6%	-$1.5M+6.0%	-$1.6M+14.4%	-$1.9M-132.8%	-$806K
Investing Cash Flow	N/A	N/A	-$31K-121.4%	-$14K-1300.0%	-$1K	$0
Financing Cash Flow	$916K+3716.7%	$24K-99.2%	$3.2M+53.8%	$2.1M+78.3%	$1.2M-32.0%	$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$277K-63.9%	-$169K+48.9%	-$331K+0.3%	-$332K-55.1%	-$214K-114.0%	-$100K+70.2%	-$336K+29.0%	-$473K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$336K+29.0%	-$473K
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$181K-24.3%	$239K+312.1%	$58K-89.0%	$526K+1095.5%	$44K+195.7%	-$46K-123.5%	$196K+227.3%	-$154K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GTHP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	28.6%-8.2pp	36.7%+559.8pp	-523.1%-547.8pp	24.7%	N/A	-94.4%
Operating Margin	-30114.3%-26586.7pp	-3527.6%+22110.9pp	-25638.5%-22722.4pp	-2916.0%-1884.7pp	-1031.4%+1571.4pp	-2602.8%
Net Margin	-34528.6%-30968.4pp	-3560.2%+29832.1pp	-33392.3%-30836.7pp	-2555.6%-2282.0pp	-273.5%+5062.6pp	-5336.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-175.4%+33.7pp	-209.1%-80.1pp	-129.0%-27.5pp	-101.5%-80.8pp	-20.7%+142.1pp	-162.8%
Current Ratio	0.19-0.1	0.29-0.3	0.62+0.3	0.29+0.2	0.10+0.0	0.08
Debt-to-Equity	-1.28+0.2	-1.44-1.4	0.000.0	-0.000.0	-0.000.0	0.00
FCF Margin	N/A	-1781.6%+9833.8pp	-11615.4%-9632.7pp	-1982.7%-143.5pp	-1839.2%+399.7pp	-2238.9%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	58.3%-9.2pp	67.5%	N/A	-200.0%	N/A	66.7%+16.7pp	50.0%	N/A
Operating Margin	-808.3%-156.2pp	-652.1%	N/A	-53300.0%	N/A	-5983.3%-4464.6pp	-1518.8%	N/A
Net Margin	-1236.7%-543.5pp	-693.2%	N/A	-105359.8%	N/A	-6.7%+1199.5pp	-1206.3%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-82.2%+4.1pp	-86.3%-86.2pp	-0.0%+76.4pp	-76.5%-19.8pp	-56.7%-56.6pp	-0.0%+23.1pp	-23.1%+12.9pp	-36.1%
Current Ratio	0.120.0	0.13-0.0	0.14-0.1	0.19+0.0	0.18-0.1	0.23-0.1	0.29-0.0	0.33
Debt-to-Equity	-1.16+0.0	-1.17+0.0	-1.19+0.1	-1.28-0.0	-1.27+0.1	-1.37+0.1	-1.44+0.1	-1.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-1050.0%	N/A

Note: Shareholder equity is negative (-$4.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.19), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

CS Diagnostics CSDX

$20.6M

Petvivo Hldgs Inc PETV

$24.2M

Biotricity Inc BTCY

$14.3M

Perimeter Medical Imaging Ai Inc PYNKF

$19.0M

PharmChem, Inc. PCHM

$17.3M

Frequently Asked Questions

What is Guided Thera's annual revenue?

Guided Thera (GTHP) reported $7K in total revenue for fiscal year 2024. This represents a -92.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Guided Thera's revenue growing?

Guided Thera (GTHP) revenue declined by 92.9% year-over-year, from $98K to $7K in fiscal year 2024.

Is Guided Thera profitable?

No, Guided Thera (GTHP) reported a net income of -$2.4M in fiscal year 2024, with a net profit margin of -34528.6%.

What is Guided Thera's earnings per share (EPS)?

Guided Thera (GTHP) reported diluted earnings per share of $-0.05 for fiscal year 2024. This represents a 28.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Guided Thera's EBITDA?

Guided Thera (GTHP) had EBITDA of -$2.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Guided Thera's gross margin?

Guided Thera (GTHP) had a gross margin of 28.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Guided Thera's operating margin?

Guided Thera (GTHP) had an operating margin of -30114.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Guided Thera's net profit margin?

Guided Thera (GTHP) had a net profit margin of -34528.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Guided Thera's operating cash flow?

Guided Thera (GTHP) generated -$1.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Guided Thera's total assets?

Guided Thera (GTHP) had $1.4M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Guided Thera spend on research and development?

Guided Thera (GTHP) invested $526K in research and development during fiscal year 2024.

How many shares does Guided Thera have outstanding?

Guided Thera (GTHP) had 65M shares outstanding as of fiscal year 2024.

What is Guided Thera's current ratio?

Guided Thera (GTHP) had a current ratio of 0.19 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Guided Thera's debt-to-equity ratio?

Guided Thera (GTHP) had a debt-to-equity ratio of -1.28 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Guided Thera's return on assets (ROA)?

Guided Thera (GTHP) had a return on assets of -175.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Guided Thera's cash runway?

Based on fiscal year 2024 data, Guided Thera (GTHP) had $388K in cash against an annual operating cash burn of $1.1M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Guided Thera's debt-to-equity ratio negative or unusual?

Guided Thera (GTHP) has negative shareholder equity of -$4.9M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Guided Thera's Piotroski F-Score?

Guided Thera (GTHP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Guided Thera's earnings high quality?

Guided Thera (GTHP) has an earnings quality ratio of 0.46x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Guided Thera cover its interest payments?

Guided Thera (GTHP) has an interest coverage ratio of -5.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.